495results about How to "Strong immune response" patented technology

The present invention is directed to methods for constructing and using in vivo and in vitro models of aspects of human immunity and, in particular, construction of a human immune system model for the testing of, for example, vaccines, adjuvants, immunotherapy candidates, cosmetics, drugs, biologics and other chemicals. The present invention comprises both in vivo and in vitro models of aspects of human immunity that are useful for assessing the interaction of substances with the immune system, and thus can be used to accelerate and improve the accuracy and predictability of, for example, vaccine, drug, biologic, immunotherapy, cosmetic and chemical development. The invention is also useful for the generation of human monoclonal and polyclonal antibodies.

Nanoparticles for providing immune responses for the treatment or prophylaxis of infection by infectious agents such as viruses, parasites, bacteria, prions and fungi are described which comprises a core including metal and / or semiconductor atoms, wherein the core is covalently linked to a plurality of ligands, the ligands including a carbohydrate residue capable of stimulating an innate immune response, a T cell helper peptide and a danger signal. This platform may then be adapted by including one or more further ligands capable of producing a specific response to a target infectious agent.

An adjuvant composition is provided that is comprised of a calcium compound, lecithin, and an acrylic polymer. Pharmaceutical compositions are provided which include an antigen and the adjuvant. Methods are provided for stimulating an immune response in a human or animal subject by administering a composition comprising an antigen and the adjuvant composition to human or animal subjects.

A method for synthesizing chimeric influenza virus-like particles (VLPs) within a plant or a portion of a plant is provided. The method involves expression of chimeric influenza HA in a plant or a portion of a plant. The invention is also directed towards a VLP comprising chimeric influenza HA protein and plants lipids. The invention is also directed to a nucleic acid encoding chimeric influenza HA as well as vectors. The VLPs may be used to formulate influenza vaccines, or may be used to enrich existing vaccines.

The present invention provides polypeptides having a composite amino acid sequence derived from a consensus sequence representing the capsid proteins of two or more circulating strains of a non-enveloped virus. In particular, the invention provides virus-like particles comprising at least one composite polypeptide. Such virus-like particles have antigenic epitopes of two or more circulating strains of a non-enveloped virus and produce an increase in antisera cross-reactivity to one or more circulating strains of the non-enveloped virus. Methods of making composite virus-like particles and vaccine formulations comprising composite virus-like particles are also disclosed.

The invention relates to the technical field of biology and specifically relates to a pseudomonas aeruginosa vaccine and a preparation method thereof. The pseudomonas aeruginosa vaccine is used for solving the technical problem that the existing pseudomonas aeruginosa vaccine at the development and clinical test stages are low in protective efficacy, high in toxicity to organisms and incapable of meeting the requirements of clinical immunology due to failure in curing infection. The technical scheme adopted to solve the technical problem is as follows: a preparation method of a novel vaccine is provided. The preparation method comprises the steps of firstly obtaining pseudomonas aeruginosa bacteria and then irradiating the bacteria by use of rays to obtain the pseudomonas aeruginosa vaccine. The pseudomonas aeruginosa vaccine is used for either preventing diseases or treating diseases, and has good application prospect.

Herein-described are various methods for making a vaccine that are made of re-assembled virus like particles (VLP). First, the VLPs are disassembled into encapsidation intermediate populations. Each encapsidation intermediate population undergoes, for instance, chemical conjugation of unique peptide or nucleic moieties to form separate populations. Thereafter, a predetermined amount of each of the several (one or more) different encapsidation intermediates from the different populations is mixed and joined, forming intact VLPs, surrounding a nucleic acid core, that are composed of different encapsidation intermediate such that the reassembled VLP displays more than one peptide or nucleic acid. The nucleic acid can function either as a scaffold alone or can be engineered for the expression of an immunomodulatory protein in a eukaryotic cell.

The invention discloses a method of preparing a bombyx mori silk fibroin specific antibody by utilizing a characteristic dodecapeptide. The method comprises the following steps: synthesizing a polypeptide with a "CGYGAGAGAGYGA" sequence, coupling the polypeptide with keyhole limpet hemocyanin (KLH) so as to obtain a complete antigen; diluting the complete antigen with normal saline, mixing the diluted complete antigen with a complete Freund's adjuvant, carrying out an emulsion treatment so as to obtain primary immunized antigen emulsion, subjecting a rabbit to a primary immunization by using the primary immunized antigen emulsion, then subjecting the rabbit to a strengthened immunization, wherein the strengthened immunization uses a strengthened immunized antigen emulsion, which is prepared by the following steps: mixing the diluted complete antigen with an incomplete Freund's adjuvant, and then carrying out an emulsion treatment so as to obtain the target product; collecting the blood of the immunized rabbit, when the antiserum titer of rabbit arrives at 1 / 10000; making the blood blocks fully contract to completely separate out the antiserum, then collecting the antiserum, and subjecting the antiserum to a centrifugation treatment so as to obtain a supernate. The antibody prepared by the invention has a strong specificity, and can be used for detection and analysis of silk fibroin in textile, and the like.

The invention relates to an Asia1 type foot-and-mouth disease recombinant virus without pathogenicity for a host and a preparation method and application thereof. A saving system is efficient eukaryotic plasmids which are constructed by gene engineering and can express exact foot-and-mouth disease virus genome RNA (Ribonucleic Acid), and therefore the foot-and-mouth disease recombinant virus can be constructed and prepared; vaccine strains with high titer and good antigen matching property can be prepared by using the plasmids, can be prepared into live vaccines or inactivated vaccines and can effectively stimulate bodies to produce immune response after being used for immunizing pigs and cattle, provide an immune protective effect on the pigs and the cattle and effectively protect GV and GII prevalent strains, the immune protection rate can reach 100 percent, and the median protective dose (PD50) is 6.34 to 13.59; and the recombinant virus has the advantages of high titer, high antigen matching property with the prevalent strains, wide antigen spectrum and high immune protection rate, does not have pathogenicity for pig and cattle hosts, does not form toxemia or expel toxin, and can be applied to prevention and control of Asia1 type foot-and-mouth disease viruses of China and neighboring countries.

The invention provides a recombinant DNA sequence, hansenula polymorpha, a preparation method for hepatitis B surface antigen, and a hepatitis B vaccine. The recombinant DNA sequence is obtained by codon optimization of coding genes of the hepatitis B virus surface antigen according to codon usage frequency of the hansenula polymorpha. The invention also provides the hansenula polymorpha comprising the recombinant DNA sequence, a method for preparing adr sub-type hepatitis B surface antigen by using the recombinant DNA sequence, and the hepatitis B vaccine. The adr sub-type hepatitis B surface antigen has high expression level of the recombinant DNA sequence. The recombinant hansenula polymorpha is fast in growth speed, has high HBsAg yield, can be fermented in high cell density by using a cheap chemically synthetic medium, has low fermentation contamination rate and is beneficial to large-scale production; and HBsAg adr vaccine provided by the invention has high trend of Th1 and Th2 type cellullar immunologic response.